2 weeks Ago By Defense World Staff
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by investment analysts at Needham & Company LLC from $202.00 to $183.00 in a research note issued to investors on Thursday,Benzinga reports.
The firm currently has a “buy” rating on the biotechnology company’s stock. Needham & Company LLC’s price target indicates a potential upside of 236.21% from the company’s current price.
A number of other brokerages have also weighed in on SRPT. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th.
Scotiabank lowered their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th.
Royal Bank of Canada downgraded Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $161.00 to $87.00 in a research report on Monday, March 31st.
Deutsche Bank Aktiengesellschaft decreased their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th.
Finally, HC Wainwright raised Sarepta Therapeutics from a “sell” rating to a “neutral” rating and set a $75.00 price objective for the company in a report on Wednesday. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock.
Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.18.Check Out Our Latest Report on SRPTSarepta Therapeutics Stock Down 7.
1 %Shares of NASDAQ:SRPT opened at $54.43 on Thursday. The company has a quick ratio of 3.
03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.
The firm has a market cap of $5.28 billion, a P/E ratio of 43.54 and a beta of 0.
79. Sarepta Therapeutics has a 12 month low of $54.26 and a 12 month high of $173.
25. The company’s 50-day moving average price is $96.95 and its two-hundred day moving average price is $113.
78. Insider Buying and SellingIn other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.
64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.
68. The trade was a 8.22 % decrease in their position.
The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.70% of the stock is owned by company insiders.
Institutional Inflows and OutflowsLarge investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC increased its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter.
Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Sarepta Therapeutics by 169.6% in the fourth quarter.
MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. increased its position in shares of Sarepta Therapeutics by 446.
2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the last quarter.
Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the 4th quarter worth approximately $36,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Sarepta Therapeutics by 164.
4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares during the last quarter. Institutional investors and hedge funds own 86.
68% of the company’s stock. Sarepta Therapeutics Company Profile (Get Free Report)Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Further ReadingFive stocks we like better than Sarepta TherapeuticsTSX Venture Exchange (Formerly Canadian Venture Exchange)Archer Aviation’s Africa Deal Could Boost ACHR StockInvesting in Construction StocksAre Short Sellers Wrong About These 3 Semiconductor Stocks?Most active stocks: Dollar volume vs share volumeBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?.
